Filing Analysis
Standard BioTools Inc. filed an 8-K to announce its financial results for the three and six months ended June 30, 2026, and provided a revenue outlook for the full year 2026.
📋 Key Facts
- Reported financial results for the second quarter (three months) and first half (six months) of fiscal year 2026 ended June 30, 2026.
- Issued a 'Full Year 2026 Revenue Outlook' as part of the disclosure.
- Filed under Items 2.02 (Results of Operations and Financial Condition) and 7.01 (Regulation FD Disclosure).
Standard BioTools Inc. filed an amended 8-K to provide the Share and Asset Purchase Agreement regarding the sale of its mass cytometry business to Multiplex Bio Inc. This divestiture is part of a broader strategic restructuring involving multiple asset sales and a proposed merger/acquisition with Treeline.
🚩 Red Flags
- Strategic fragmentation: The company is simultaneously divesting its mass cytometry business, potentially selling its microfluidics business, and engaging in a transaction with 'Treeline'.
- Execution risk: High uncertainty regarding the ability to close multiple complex transactions (Mass Cytometry sale and Treeline deal) in a timely manner.
- Regulatory/Legal risk: Potential for stockholder litigation related to the sales and the Treeline transaction.
- Nasdaq listing risk: The company explicitly notes the risk that it could fail to maintain its Nasdaq listing.
📋 Key Facts
- The company entered into a Share and Asset Purchase Agreement with Multiplex Bio Inc. dated July 28, 2026.
- The transaction involves the disposition of Standard BioTools' mass cytometry business.
- The filing is an amendment (8-K/A) to supplement the original 8-K filed on July 28, 2026.
- The company has also filed a Form S-4 regarding a separate 'Treeline transaction'.
- Management's attention is being diverted from ongoing operations due to multiple pending transactions (Mass Cytometry sale and Treeline deal).
Standard BioTools Inc. has entered into a series of complex restructuring agreements involving the termination of major royalty/earnout streams from Illumina and the sale of its Mass Cytometry business to Multiplex Bio Inc.
🚩 Red Flags
- Asset disposition for non-cash consideration (promissory note instead of cash).
- Contingent liability: Company may be forced to provide up to $10 million in working capital to the buyer.
- Significant termination fee ($1M) and expense reimbursement obligations if the Mass Cytometry deal fails.
- High complexity/multiple moving parts: The deals are contingent on a separate pending merger with Treeline Biosciences.
📋 Key Facts
- Received $30 million cash payment from Illumina in exchange for waiving 2026 earnout rights and terminating royalty/license agreements.
- Agreed to sell the 'Mass Cytometry' business to Multiplex Bio Inc. for an aggregate purchase price of $5 million via a promissory note (6% interest, 5-year maturity).
- The Mass Cytometry transaction involves no cash consideration at closing; instead, it is structured as a promissory note.
- Standard BioTools may be required to provide up to $10 million in working capital to Multiplex Bio if the buyer cannot secure financing.
- Potential for an additional $5 million contingent payment if Multiplex Bio completes a qualifying sale within 10 years.
- The Mass Cytometry sale is subject to stockholder approval and the consummation of a pending merger with Treeline Biosciences, Inc.
Standard BioTools Inc. received a notification from Nasdaq stating it failed to meet the minimum $1.00 bid price requirement after closing below that threshold for 30 consecutive business days. The company has been granted an automatic 180-day compliance period ending January 19, 2027.
🚩 Red Flags
- Delisting notice regarding minimum bid price requirement.
- Share price has been below $1.00 for 30 consecutive business days, indicating significant downward momentum.
- The company explicitly mentions a reverse stock split as a potential method to cure the deficiency.
📋 Key Facts
- Received notice from Nasdaq Listing Qualifications Department on July 22, 2026.
- Failure to meet the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1).
- The company has a 180-calendar day period (until January 19, 2027) to regain compliance by maintaining a $1.00 bid price for at least 10 consecutive business days.
- Potential secondary recourse involves transferring listing to the Nasdaq Capital Market if the minimum bid requirement is waived under specific conditions.
Standard BioTools Inc. announced its financial results for the three and nine months ended September 30, 2025. The filing includes disclosures regarding operational restructuring and updated revenue outlooks for the full year 2025.
🚩 Red Flags
- Mention of 'Operational Restructuring' often implies cost-cutting or significant changes to business structure, which can be a sign of financial distress or declining margins.
- The inclusion of restructuring details alongside revenue outlooks suggests volatility in the company's current trajectory.
📋 Key Facts
- Reported financial results for the three and nine months ended September 30, 2025.
- Disclosed details concerning 'Operational Restructuring'.
- Provided a 'Full Year 2025 Revenue Outlook'.
- Filed via Items 2.02 (Results of Operations) and 7.01 (Regulation FD Disclosure).
Standard BioTools Inc. has announced a restructuring plan involving a 15% reduction in its global workforce to improve operational efficiency and align with current revenue projections. The company expects approximately $7.5 million in severance and termination costs related to this initiative.
🚩 Red Flags
- Workforce reduction suggests a need to align costs with declining or stagnant revenue projections.
- Potential for additional unquantified costs related to the restructuring process.
📋 Key Facts
- Commenced restructuring plan on September 13, 2025.
- Reduction-in-force (RIF) affects approximately 15% of the total global workforce.
- Estimated restructuring expenses are approximately $7.5 million, primarily consisting of cash severance and termination benefits.
- Restructuring is intended to align operating costs with current revenue projections.
Standard BioTools Inc. announced a restructuring plan to consolidate R&D capabilities from South San Francisco to Singapore and implement a reduction-in-force (RIF) affecting U.S. employees, including management.
🚩 Red Flags
- Reduction in workforce includes members of the management team, indicating potential leadership instability or significant organizational shift.
- Relocation of R&D capabilities from the US to Singapore may signal a major strategic pivot or cost-cutting necessity.
📋 Key Facts
- Consolidation of South San Francisco R&D into Singapore facility to co-locate with manufacturing.
- Reduction-in-force (RIF) targeting certain U.S. employees in the R&D function and management team.
- Estimated restructuring costs: ~$3.6 million total ($0.9 million is non-cash share-based awards).
- Restructuring aims to improve operational efficiency and reduce operating costs.
Standard BioTools Inc. filed an 8-K to announce its financial results for the three and six months ended June 30, 2025. The filing includes a press release containing operational updates and updated revenue outlooks for the full year 2025.
📋 Key Facts
- Report date: August 11, 2025
- Reporting period: Three and six months ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- The company provided a 'Full Year 2025 Revenue Outlook' under Item 7.01.
Standard BioTools Inc. announced the approval of significant RSU retention awards for its CEO, Michael Egholm, and CFO, Alex Kim, effective August 1, 2025. The filing also includes an increase to the CFO's target annual performance bonus.
🚩 Red Flags
- Retention awards for top executives can sometimes signal underlying concerns regarding executive turnover or stability, though they are standard practice in micro-cap/mid-cap biotech.
📋 Key Facts
- CEO Michael Egholm granted 3,000,000 RSUs; 25% vests Aug 1, 2026, with remaining 75% vesting in three equal annual installments thereafter.
- CFO Alex Kim granted 1,500,000 RSUs; 40% vests July 20, 2026, and 60% vests July 20, 2027.
- CFO Alex Kim's target annual performance bonus increased to 80% of base salary, retroactive to January 1, 2025.
- Awards are subject to the Company’s Amended and Restated 2011 Equity Incentive Plan.
Standard BioTools Inc. has entered into a definitive agreement to sell its aptamer-based and functional proteomics business (SomaLogic, Inc.) to Illumina, Inc. for up to $425 million in cash and earnouts.
🚩 Red Flags
- Significant divestiture of a core business segment (aptamer-based/proteomics).
- Transaction is contingent on significant revenue targets for the earnout component.
- Long closing window (expected H1 2026) introduces execution and regulatory risk.
📋 Key Facts
- Transaction value: Up to $425 million ($350M upfront cash + $75M contingent earnout).
- Assets being sold: All equity interests of SomaLogic, Inc., Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd.
- Assets being retained: Mass cytometry and microfluidics businesses.
- Earnout criteria: Based on net revenue from SomaScan assay services and SOMAmer-based kits in FY2025 and FY2026.
- Additional terms: Includes royalty agreements for NGS library prep kits and Single SOMAmers, a license agreement for Single SOMAmer reagents, and a transition services agreement.
- Reverse termination fee: $14.5 million payable by Illumina if the deal is terminated under specified circumstances.
- Expected closing: First half of 2026, subject to regulatory (HSR Act) approval.
Standard BioTools Inc. held its 2025 Annual Meeting of Stockholders on June 18, 2025, reporting the results of several shareholder votes including director elections and compensation approvals.
📋 Key Facts
- The company successfully increased the number of shares reserved under its Amended and Restated 2011 Equity Incentive Plan by 17,400,000 shares.
- Kathy Hibbs and Frank Witney, Ph.D. were elected to serve as Class III directors until the 2028 annual meeting.
- Shareholders approved the advisory vote on executive compensation for the year ended December 31, 2024.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Voting power represented at the meeting was approximately 86.06% of total shares outstanding.
Standard BioTools Inc. filed an 8-K to announce its quarterly financial results for the period ending March 31, 2025 and provided an updated revenue outlook for the full year 2025.
📋 Key Facts
- Reported financial results for the three months ended March 31, 2025 via press release (Exhibit 99.1).
- Issued an 'Updated Full Year 2025 Revenue Outlook' under Item 7.01.
- Filing includes standard forward-looking statement disclaimers.
Standard BioTools Inc. filed an 8-K to announce its financial results for the three months and fiscal year ended December 31, 2024, alongside a revenue outlook for the full year 2025.
📋 Key Facts
- Reported financial results for Q4 and Full Year 2024 on February 26, 2025.
- Included a 'Full Year 2025 Revenue Outlook' within the disclosure.
- The filing includes Exhibit 99.1 containing the detailed press release.
Standard BioTools Inc. issued a press release and updated its investor presentation containing preliminary, unaudited financial results for the three months and fiscal year ended December 31, 2024.
🚩 Red Flags
- Financial results are preliminary and unaudited, meaning they are subject to change upon completion of audits.
📋 Key Facts
- Preliminary financial results released for Q4 and FY 2024 as of January 13, 2025.
- Results are unaudited and subject to adjustment following annual audit procedures.
- Company updated its investor presentation (Exhibit 99.2) for general corporate use.
Standard BioTools Inc. announced that Chief Commercial Officer Jeremy Davis will depart the company effective February 1, 2025, following a mutual agreement. The departure includes a severance package consisting of salary continuation and accelerated equity vesting.
🚩 Red Flags
- Departure of a key C-suite officer (Chief Commercial Officer) can signal internal shifts or changes in commercial strategy.
📋 Key Facts
- Jeremy Davis is stepping down as Chief Commercial Officer (CCO) effective February 1, 2025.
- The departure was mutually determined between the Company and Mr. Davis.
- Severance includes 12 months of base salary totaling $441,000.
- Mr. Davis will receive his full 2024 fiscal year bonus of $169,785.
- A pro-rated lump-sum payment of target bonus ($21,264.65) and COBRA premium coverage are included in the severance terms.
- All outstanding unvested equity awards will undergo 100% vesting acceleration.
Standard BioTools Inc. has agreed to pay $890,000 in attorneys' fees and expenses to resolve a motion filed by plaintiffs in a class action lawsuit related to SomaLogic, Inc. The settlement aims to avoid further litigation costs regarding the 'Mooting Disclosures' from 2023.
🚩 Red Flags
- Ongoing litigation history (though this specific motion is being resolved).
📋 Key Facts
- Settlement amount: $890,000 for attorneys' fees and expenses in full satisfaction of claims related to Mooting Disclosures.
- The dispute originated from a Verified Class Action Complaint filed on December 13, 2023, regarding alleged misleading proxy statements by SomaLogic, Inc.
- The settlement was reached via stipulation and approved by the Delaware Court on December 19, 2024.
- SomaLogic denies all allegations of wrongdoing.
Standard BioTools Inc. has announced the permanent appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. As part of this transition, Mr. Kim will step down from his role as Chief Operating Officer, and that position will be vacated.
🚩 Red Flags
- Vacating the COO position may indicate a restructuring of management layers or organizational streamlining.
📋 Key Facts
- Alex Kim appointed full-time CFO effective November 11, 2024.
- Mr. Kim has been serving as Interim CFO since September 1, 2024.
- The Chief Operating Officer (COO) position will be vacated upon the transition.
- Mr. Kim will continue to serve as Principal Financial Officer and Principal Accounting Officer.
- No additional compensation is being provided for the new role.
Standard BioTools Inc. issued an 8-K to report its financial results for the three and nine months ended September 30, 2024, and provided an updated revenue outlook for fiscal year 2024.
🚩 Red Flags
- Interim CFO status (Hanjoon Alex Kim) may indicate recent management instability or transition in the finance department.
📋 Key Facts
- Reported financial results for the three and nine months ended September 30, 2024.
- Issued an 'Updated FY 2024 Revenue Outlook' via Regulation FD disclosure.
- The filing was signed by Hanjoon Alex Kim, COO and Interim CFO.
Standard BioTools Inc. updated its investor presentation on September 5, 2024. This is a routine disclosure intended for use in general corporate presentations.
📋 Key Facts
- The company updated its investor presentation as of September 5, 2024.
- The update was filed under Item 7.01 (Regulation FD Disclosure).
- The presentation is intended for general corporate use and will be available on the company's website.
Standard BioTools Inc. has approved a new 2024 Change of Control and Severance Plan, effective through August 4, 2026. The plan establishes enhanced severance benefits for key members of the executive leadership team in the event of a qualifying termination or change in control.
🚩 Red Flags
- The establishment of significant severance packages often signals that management is preparing for a potential sale or merger (Change of Control).
- Enhanced 'Golden Parachute' provisions can create agency conflicts by incentivizing executives to pursue acquisitions that benefit them personally even if not optimal for shareholders.
📋 Key Facts
- The Board approved the '2024 Change of Control and Severance Plan' on August 27, 2024.
- The plan term extends until August 4, 2026.
- Eight specific executives entered into Participation Agreements: Hanjoon Alex Kim (COO), David King (SVP R&D), Agnieszka Gallagher (CLO), Mona Abou-Sayed (SVP Business System), Jeremy Davis (CCO), Anders Davas (SVP Global Operations), Betsy Jensen (CHRO), and Sean Mackay (CBO).
- Standard termination benefits include 100% of annual base salary for 12 months, pro-rated target bonus, and 12 months of health coverage.
- Change in Control (CIC) termination benefits increase to 150% of the sum of base salary and target cash incentive, with up to 18 months of health coverage and 100% equity vesting acceleration.
Standard BioTools Inc. announced the resignation of its Senior Vice President and CFO, Jeffrey Black, effective August 31, 2024. The company has appointed current COO Alex Kim to serve as Interim CFO starting September 1, 2024.
🚩 Red Flags
- Sudden departure of the Chief Financial Officer in a micro-cap/mid-cap environment can sometimes precede financial scrutiny, though not explicitly stated here.
- Transition to an interim CFO creates temporary leadership gap in the finance function.
📋 Key Facts
- Jeffrey Black resigned as SVP and CFO (principal financial/accounting officer) on July 26, 2024.
- Resignation is effective August 31, 2024.
- The resignation was reportedly not due to disagreements regarding operations, policies, or practices.
- Alex Kim (current COO) will serve as Interim CFO starting September 1, 2024.
- The company has initiated a search for a permanent successor.
Standard BioTools Inc. issued a press release on July 31, 2024, disclosing financial results for the second quarter of 2024 and providing an updated revenue outlook for the full fiscal year 2024.
🚩 Red Flags
- Update to revenue outlook often implies a deviation from previous guidance, which can lead to market volatility.
📋 Key Facts
- Reported financial results for the three and six months ended June 30, 2024.
- Issued an 'Updated FY 2024 Revenue Outlook' via press release dated July 31, 2024.
- The filing includes information under Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure).
Standard BioTools Inc. held its 2024 Annual Meeting of Stockholders on June 27, 2024. The meeting resulted in the election of Class II directors and the approval of several shareholder proposals, including an amendment to the company's equity incentive plan.
📋 Key Facts
- Annual Meeting held on June 27, 2024.
- Stockholders approved an amendment to the Amended and Restated 2011 Equity Incentive Plan, increasing reserved shares by 19,125,000.
- Troy Cox and Fenel M. Eloi were elected as Class II directors.
- Shareholders ratified the appointment of PricewaterhouseCoopers LLP (PwC) as independent auditors for the fiscal year ending Dec 31, 2024.
- Advisory vote on executive compensation was approved.
- Voting quorum represented approximately 79.19% of total voting power.
Madryn Health Partners (Cayman Master), LP has irrevocably withdrawn its intent to nominate director candidates and submit a business proposal at the upcoming 2024 annual meeting. This marks a cessation of the activist campaign initiated by the entity on March 15, 2024.
📋 Key Facts
- Madryn Health Partners (Cayman Master), LP withdrew its notice to nominate director candidates and submit a business proposal.
- The withdrawal applies to the upcoming 2024 annual meeting of stockholders.
- The Company will distribute revised proxy cards to reflect this withdrawal.
Standard BioTools Inc. filed an 8-K to announce its quarterly financial results for the three months ended March 31, 2024. The filing incorporates a press release containing operational updates and the company's outlook for the remainder of 2024.
📋 Key Facts
- Reporting period: Three months ended March 31, 2024.
- Filing date: May 8, 2024.
- The filing includes information regarding results of operations and financial condition (Item 2.02).
- The filing includes a 'Outlook for 2024' section under Regulation FD disclosure (Item 7.01).
Standard BioTools Inc. announced an operational restructuring plan involving a 10% reduction-in-force and the elimination of certain senior management positions following its merger with SomaLogic, Inc. The company expects to incur $10 million to $11 million in total costs related to this restructuring.
🚩 Red Flags
- Significant restructuring costs ($10M-$11M) following a recent merger indicate integration challenges or cost pressures.
- Elimination of senior management positions can signal leadership instability or significant shifts in corporate strategy.
📋 Key Facts
- Reduction-in-force affects approximately 10% of the total workforce.
- Elimination of certain senior management positions as part of post-merger integration.
- Estimated restructuring expenses: $10 million to $11 million.
- Of the estimated costs, approximately $4 million are non-cash expenses related to vesting share-based awards.
- Costs are expected to be payable over the next three quarters.
Standard BioTools Inc. completed an exchange agreement to retire all outstanding Series B-1 and B-2 Convertible Preferred Stock in exchange for 92,930,553 shares of common stock issued to institutional investors. This transaction effectively eliminates the preferred liquidation preferences and converts them into significant common equity.
🚩 Red Flags
- Massive dilution: The issuance of ~92.9 million common shares represents a significant increase in the total share count, which typically dilutes existing common shareholders.
- Concentration of ownership: Large institutional investors (Casdin and Viking) have gained substantial direct equity positions through this exchange.
📋 Key Facts
- Exchange completed on March 18, 2024.
- Investors (Casdin Partners and Viking Global) exchanged all Series B-1 and B-2 Preferred Stock for 92,930,553 shares of common stock.
- The transaction was approved by a special committee of independent directors.
- Series B-1 and B-2 Preferred Stock have been eliminated via Certificates of Elimination filed in Delaware.
- Two directors (Eli Casdin and Fenel Eloi) were assigned to Class I and Class II board seats respectively following the exchange.
Standard BioTools Inc. filed an 8-K to announce its financial results for the three months and fiscal year ended December 31, 2023. The filing incorporates a press release containing quarterly/annual earnings data and forward-looking guidance for 2024.
📋 Key Facts
- Report date: February 28, 2024
- Reporting period: Three months and fiscal year ended December 31, 2023
- Includes 'Outlook for 2024' guidance under Item 7.01
- Financial results provided via Exhibit 99.1 press release
Standard BioTools Inc. filed an amendment to its previous 8-K to include the required financial statements and pro forma information following its completed acquisition of SomaLogic, Inc.
🚩 Red Flags
- None identified in this specific amendment; the filing is procedural to satisfy Item 9.01 requirements.
📋 Key Facts
- The filing is an Amendment (Form 8-K/A) to a report originally filed on January 5, 2024.
- Standard BioTools completed the acquisition of SomaLogic, Inc. via a merger with Martis Merger Sub, Inc.
- Includes audited consolidated financial statements for SomaLogic for years ended Dec 31, 2022 and 2021 (Exhibits 99.1, 99.2).
- Includes unaudited pro forma condensed combined financial statements as of Dec 31, 2022, and nine months ended Sept 30, 2023 (Exhibit 99.3).
- The acquisition was pursuant to a Merger Agreement dated October 4, 2023.
Standard BioTools Inc. issued a press release containing preliminary financial results for the three months and fiscal year ended December 31, 2023. The company also updated its investor presentation to reflect current corporate information.
📋 Key Facts
- Preliminary financial results released for Q4 and FY 2023 (ended Dec 31, 2023).
- Updated investor presentation issued on January 8, 2024.
- Filing includes Exhibits 99.1 (Press Release) and 99.2 (Investor Presentation).
Standard BioTools Inc. has completed its merger with SomaLogic, Inc., resulting in the integration of SomaLogic as a wholly owned subsidiary. The transaction involved significant changes to the company's board composition and authorized share structure.
🚩 Red Flags
- Significant dilution potential due to the issuance of new shares for the merger and the increase in authorized share count.
- Board turnover involving multiple resignations following a major transaction.
📋 Key Facts
- Merger between Standard BioTools Inc. and SomaLogic, Inc. was completed on January 5, 2024.
- SomaLogic shareholders received 1.11 shares of Standard BioTools for each share of SomaLogic common stock.
- Standard BioTools increased authorized shares from 400 million to 600 million via a Charter Amendment approved by stockholders on January 4, 2024.
- The company amended its 2011 Equity Incentive Plan to increase reserved shares by 15,000,000.
- Three directors (Carlos Paya, Laura Clague, and Martin Madaus) resigned from the Standard BioTools Board as part of the merger.